<< Back
Abiomed Receives Conditional FDA Approval for Study with Impella 2.5 in Reducing Heart Muscle Damage Following PCI in STEMI Patients

DANVERS, Mass., Dec 02, 2010 (BUSINESS WIRE) --

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced it has received conditional approval from the U.S. Food and Drug Administration (FDA) to begin MINI-AMI, a prospective, randomized, controlled multi-site trial to assess the potential role of the Impella(R) 2.5 in reducing infarct size in patients with ST-elevation myocardial infarction (STEMI). The primary objective of this study is to evaluate whether the adjunctive use of the Impella 2.5 for 24 hours following primary percutaneous intervention (PCI) for STEMI has the potential to limit the infarction of at-risk myocardium compared to primary PCI with routine post-PCI care. According to the American Heart Association (AHA), 400,000 patients in the U.S. suffer from STEMIs every year.

"This pilot study will determine whether the Impella 2.5 can be the first device to actually shrink infarct size," said Principle Investigator Jeffrey Moses, M.D., New York-Presbyterian Hospital and Columbia University Medical Center. "Today, heart attack survivors can suffer considerable subsequent disability from damaged heart muscle. The intent of this study is to investigate the unique unloading capabilities of Impella 2.5 and its effect in potentially reducing infarct size and improving quality of life for patients."

"According to the AHA, within five years after surviving your first heart attack, 33% of men and 43% of women will die," said Michael R. Minogue, Chairman, President and Chief Executive Officer, Abiomed. "This will be the first Impella study to evaluate the potential therapeutic benefits of unloading and reducing the oxygen demand on the heart muscle. We are excited to explore more clinical benefits of Impella with this new, hemodynamically stable patient population."

The primary endpoint of the study will be a cardiac MRI-assessed ratio of the final infarct area to the total area of myocardium that was at risk. This ratio will be measured at three to five days after treatment and then again at 90 days. A total of 50 patients at five hospital sites will be randomized to Impella 2.5 support or the institution's standard of care with no circulatory support post-PCI. The study is based on the hypothesis that Impella's ability to directly unload the left ventricle will reduce overall infarct area relative to the total area at risk which has been demonstrated in previous animal studies.

The MINI-AMI study will enroll patients with acute anterior STEMI or large inferior STEMI, primary PCI performed within five hours of the onset of symptoms, patients undergoing emergent primary PCI of one culprit lesion in one major coronary vessel, and successful revascularization of the native coronary artery at the end of PCI.

A recently published clinical study, "Prognostic Significance of the Occurrence of Acute Heart Failure After Successful Primary Percutaneous Coronary Intervention" by L. Savic, et al., published in the Journal of Invasive Cardiology, studied 1,074 consecutive STEMI patients who had no signs of heart failure at admission, were not in cardiogenic shock at admission and were treated with successful PCI. This study serves as a reference for the MINI-AMI patient population and demonstrated the following:

  • Acute heart failure (AHF) during hospitalization occurred in 11.1% of patients in this study;
  • 81.8% of these AHF patients died in the first 30 days;
  • In some patients, even timely and successful PCI cannot prevent extensive myocardial damage;
  • Patients who developed AHF had a lower ejection fraction;
  • There was no significant difference between groups regarding the duration of symptoms or door-to-needle time.

The study concluded that even after successful PCI, the occurrence of AHF during hospitalization remains an independent predictor of 30-day and one year mortality. Additionally, the study noted that further investigation is needed to evaluate whether modification of post-procedural treatment can reduce the incidence of AHF.

1. Meyns, et al. Left ventricular support by Catheter-Mounted axial flow pump reduces infarct size. JACC, 2003.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recently filed Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

SOURCE: Abiomed, Inc.

Abiomed, Inc.
Aimee Maillett, 978-646-1553
Public Relations Specialist
ir@abiomed.com
Could not find file '\\aws.nasdaqomx.com\irwebpro\content3\IRXMLDATA\95\95629\Disclaimers.xml'.